

## Special Issue

# Bladder Dysfunction: From Molecular Pathology to Therapeutic Approaches

### Message from the Guest Editor

The Special Issue “Bladder Dysfunction: From Molecular Pathology to Therapeutic Approaches” is related to new insights into the mechanism of bladder dysfunction from molecular and cellular events leading from overactive bladder to underactive bladder. Bladder dysfunction is a term used for a range of problems with the way the bladder holds and releases urine. In the practice of physical medicine and rehabilitation, voiding disorders are usually a result of spinal cord injury (SCI), cerebrovascular accident (CVA), dementia, bladder outlet obstruction, or aging. Incontinence and urinary retention can cause social embarrassment and added morbidity, such as infections, stones, or renal injury. Evaluation of bladder dysfunction can involve laboratory studies, radiography, ultrasonography, cystometry, and electromyography. Research into biomarkers for diagnostics, prognostics, and the prediction of response to treatment/relapse are also invited from any stage of development from discovery to validation/replication studies. Original research and comprehensive reviews are welcomed.

### Guest Editor

Dr. Yung-Shun Juan

Department of Urology, College of Medicine, Kaohsiung Medical University, Kaohsiung 80708, Taiwan

### Deadline for manuscript submissions

closed (15 August 2022)



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/91513](https://mdpi.com/si/91513)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLUS / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2024).